A multivalent mRNA monkeypox virus vaccine (BNT166) protects mice and macaques from orthopoxvirus disease
Cell · 2024-03 · 187 (6) · 1363-1373.e12
DOI: 10.1016/j.cell.2024.01.017 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell, 2024-03. Verfasst von Adam Zuiani und 26 weiteren Autor:innen. Beteiligte Einrichtung: BioNTech US, Cambridge, MA 02139, USA. Hauptthemen laut MEDLINE: Monkeypox virus, Mpox, Monkeypox, Smallpox Vaccine. Die Arbeit wurde bisher 163-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
In response to the 2022 outbreak of mpox driven by unprecedented human-to-human monkeypox virus (MPXV) transmission, we designed BNT166, aiming to create a highly immunogenic, safe, accessible, and scalable next-generation vaccine against MPXV and related orthopoxviruses. To address the multiple viral forms and increase the breadth of immune response, two candidate multivalent mRNA vaccines were evaluated pre-clinically: a quadrivalent vaccine (BNT166a; encoding the MPXV antigens A35, B6, M1, H3) and a trivalent vaccine (BNT166c; without H3). Both candidates induced robust T cell responses and IgG antibodies in mice, including neutralizing antibodies to both MPXV and vaccinia virus. In challenge studies, BNT166a and BNT166c provided complete protection from vaccinia, clade I, and clade IIb MPXV. Furthermore, immunization with BNT166a was 100% effective at preventing death and at suppressing lesions in a lethal clade I MPXV challenge in cynomolgus macaques. These findings support the clinical evaluation of BNT166, now underway (NCT05988203).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- BioNTech US, Cambridge, MA 02139, USA.
- BioNTech SE, Mainz, Germany.
- Southern Research, Birmingham, AL, USA.
- BioQual, Inc, Rockville, MD, USA.
- BioNTech SE, Mainz, Germany; HI-TRON - Helmholtz Institute for Translational Oncology Mainz by DKFZ, Mainz, Germany.
- BioNTech SE, Mainz, Germany; TRON gGmbH - Translational Oncology at the University Medical Center of the Johannes Gutenberg University, Mainz, Germany. Electronic address: ugur.sahin@biontech.de.
Zitieren
APA
Zuiani, A., Dulberger, C. L., De Silva, N. S., Marquette, M., Lu, Y. J., Palowitch, G. M., Dokic, A., Sanchez-Velazquez, R., Schlatterer, K., Sarkar, S., Kar, S., Chawla, B., Galeev, A., Lindemann, C., Rothenberg, D. A., Diao, H., Walls, A. C., Addona, T. A., Mensa, F., …, & Poran, A. (2024). A multivalent mRNA monkeypox virus vaccine (BNT166) protects mice and macaques from orthopoxvirus disease. Cell, 187(6), 1363-1373.e12. https://doi.org/10.1016/j.cell.2024.01.017
Vancouver
Zuiani A, Dulberger CL, De Silva NS, Marquette M, Lu YJ, Palowitch GM, et al. A multivalent mRNA monkeypox virus vaccine (BNT166) protects mice and macaques from orthopoxvirus disease. Cell. 2024;187(6):1363-1373.e12. doi:10.1016/j.cell.2024.01.017
BibTeX
@article{Zuiani2024,
author = {Zuiani, Adam and Dulberger, Charles L and De Silva, Nilushi S and Marquette, Meghan and Lu, Yu-Jung and Palowitch, Gavin M and Dokic, Anja and Sanchez-Velazquez, Ricardo and Schlatterer, Katja and Sarkar, Sanjay and Kar, Swagata and Chawla, Bhavna and Galeev, Alibek and Lindemann, Claudia and Rothenberg, Daniel A and Diao, Huitian and Walls, Alexandra C and Addona, Theresa A and Mensa, Federico and Vogel, Annette B and Stuart, Lynda M and van der Most, Robbert and Srouji, John R and Türeci, Özlem and Gaynor, Richard B and Şahin, Uğur and Poran, Asaf},
title = {A multivalent mRNA monkeypox virus vaccine (BNT166) protects mice and macaques from orthopoxvirus disease},
journal = {Cell},
year = {2024},
volume = {187},
number = {6},
pages = {1363--1373.e12},
doi = {10.1016/j.cell.2024.01.017}
}
EUVIMED